CONTRIBUTION AND SATISFACTION OF INDEBTEDNESS AGREEMENTContribution and Satisfaction of Indebtedness Agreement • November 6th, 2024 • Semnur Pharmaceuticals, Inc. • Blank checks • California
This CONTRIBUTION AND SATISFACTION OF INDEBTEDNESS AGREEMENT (this “Agreement”), entered into as of August 30, 2024 (the “Agreement Date”), is made and entered into by and between SCILEX HOLDING COMPANY, a Delaware corporation (“Scilex”), and SEMNUR PHARMACEUTICALS, INC., a Delaware corporation and wholly owned subsidiary of Scilex (“Semnur”).
CONTRIBUTION AND SATISFACTION OF INDEBTEDNESS AGREEMENTContribution and Satisfaction of Indebtedness Agreement • September 14th, 2022 • Sorrento Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This CONTRIBUTION AND SATISFACTION OF INDEBTEDNESS AGREEMENT (this “Agreement”), entered into as of September 12, 2022 (the “Agreement Date”), is by and among SORRENTO THERAPEUTICS, INC., a Delaware corporation (the “Sorrento”), SCILEX HOLDING COMPANY, a direct wholly owned subsidiary of Sorrento (“Scilex”), and SCILEX PHARMACEUTICALS, INC., an indirect wholly owned subsidiary of Sorrento and direct wholly owned subsidiary of Scilex (“Scilex Pharma”).
CONTRIBUTION AND SATISFACTION OF INDEBTEDNESS AGREEMENTContribution and Satisfaction of Indebtedness Agreement • September 13th, 2022 • Vickers Vantage Corp. I • Biological products, (no disgnostic substances) • California
This CONTRIBUTION AND SATISFACTION OF INDEBTEDNESS AGREEMENT (this “Agreement”), entered into as of September 12, 2022 (the “Agreement Date”), is by and among SORRENTO THERAPEUTICS, INC., a Delaware corporation (the “Sorrento”), SCILEX HOLDING COMPANY, a direct wholly owned subsidiary of Sorrento (“Scilex”), and SCILEX PHARMACEUTICALS, INC., an indirect wholly owned subsidiary of Sorrento and direct wholly owned subsidiary of Scilex (“Scilex Pharma”).
